ArticleInternational journal of cancer2026
Arrhythmic expression signatures of circadian clock-associated transcription factors and chronic circadian disruption contribute to advanced prostate cancer growth.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Chrono-immunotherapy in genitourinary oncology: From emerging evidence to clinical translation (Review).Oncology letters · 2026Review
- Arrhythmic expression signatures of circadian clock-associated transcription factors and chronic circadian disruption contribute to advanced prostate cancer growth.International journal of cancer · 2026Article
- Night work and cancer risk: results from the ELSA-Brasil worker cohort.Revista de saude publica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Disruption of circadian rhythms due to night-shift work is classified as a probable carcinogen for cancers of the breast, prostate, and colorectum by the International Agency for Research on Cancer. Global epidemiological studies link chronic circadian clock disruption to increased risk of prostate cancer via hormone and metabolic dysregulation. This study investigated and compared the circadian expression patterns of core-circadian controlled genes (CCCGs) and nuclear receptors (NRs) under a normal 12-h light/dark cycle in normal mouse prostate and advanced androgen-insensitive prostate tumors derived from a transgenic mouse model of prostate adenocarcinoma (TGMAP). Our results showed that a total of eight CCCGs and 22 NRs exhibited rhythmic oscillations in the normal mouse prostate. In contrast, the rhythmic expressions of CCCGs and NRs were significantly disrupted in TGMAP prostate tumors, with a concurrent loss of androgen receptor expression. Circadian administration of cisplatin at a specific morning time point (chrono-chemotherapy), as applied in TGMAP tumor-bearing mice, demonstrated optimal antitumor efficacy, which correlated with the circadian rhythmic expression of DNA damage repair genes. Finally, we showed that chronic jet-lag conditions could promote the oncogenic growth of hormone-sensitive VCaP-derived xenograft tumors, with a correlation to elevated serum androgen levels and increased expression of enzyme genes involved in intratumoral androgen biosynthesis. Together, this study demonstrated that advanced prostate tumors exhibited dysregulated circadian transcriptional networks, as shown by their disrupted expression of CCCGs and NRs. The potential therapeutic application of chrono-chemotherapy in advanced prostate cancer management and the disruption of circadian rhythms under chronic jet-lag conditions could enhance prostate cancer growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.